Organon & Co. OGN

What this company does

Organon & Co. sells a portfolio of over 70 products across women's health and general medicines, including biosimilars, reaching over 140 countries and territories. It sells these products through channels including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. It operates six manufacturing facilities, located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. As of December 31, 2025, it had over 10,000 employees worldwide, with approximately 1,500, or 15%, in the United States, including Puerto Rico. Its women's health portfolio is sold by prescription primarily in two therapeutic areas: contraception, with key brands such as Nexplanon and NuvaRing, and fertility, with key brands such as Follistim AQ. Its biosimilars portfolio spans immunology and oncology-related treatments. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology and non-opioid pain management, including Emgality and Vtama cream 1%.

Written from the business description in Organon & Co.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.